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Further Progress to Clinical Application*Thomas H. Schindler, MD,y Vasken Dilsizian, MDzP ositron emission tomography (PET) hasevolved as a mainstay to identify and charac-terize the coronary artery disease (CAD)
process (1). The concurrent ability of PET with radio-
tracer kinetic modeling to determine myocardial
blood ﬂow (MBF) at rest and during vasomotor stress
enables the calculation of regional myocardial ﬂow
reserve (MFR) as an adjunct to the visual interpreta-
tion of myocardial perfusion studies. Adding quantiﬁ-
cation of hyperemic MBF and MFR by PET imaging to
the visual analysis of myocardial perfusion identiﬁes
reduced coronary vasodilator capacity as a func-
tional precursor of the CAD process and measures
its response to preventive medical intervention,
improves detection and quantiﬁcation of the extent
and severity of the burden of CAD, and potentially
assesses the ﬂow-limiting effect of single lesions in
multivessel CAD (1).SEE PAGE 1464In this issue of the Journal, Danad et al. (2) report
optimal cutoff values of [15O]H2O PET-determined
hyperemic MBF and MFR of 2.3 and 2.50 ml/g/min,
respectively, in a clinical cohort of 330 patients with
ﬂow-limiting coronary artery stenosis as evidenced
by invasively measured fractional ﬂow reserve (FFR).
Quantitative [15O]H2O PET-derived MBF data pro-
vided an accuracy of 85% for detecting ﬂow-limiting
CAD as deﬁned by an abnormal FFR.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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this paper to disclose.Hyperemic MBF proved more accurate than MFR in
detecting ﬂow-limiting stenoses on both per-patient
and per-vessel analysis. Of all patients with FFR-
deﬁned, functionally limiting stenosis, only 13%
were missed by quantitative hyperemic MBF.
Moreover, a normal [15O]H2O PET hyperemic MBF of
>2.3 ml/g/min excluded the presence of ﬂow-limiting
stenosis with a high negative predictive value
(90% per patient and 95% per vessel).
Although [15O]H2O PET-derived cutoff values are
encouraging, it remains uncertain how these thresh-
olds for hyperemic ﬂows using [15O]H2O compare
with other ﬂow tracers, such as 13N-ammonia and
82rubidium, for accurate diagnosis of CAD (1,3).
As for the reported optimal cutoff values of PET-
determined hyperemic MBF and MFR with [15O]H2O,
it remains uncertain whether stenotic ﬂow-limiting
effects contribute mildly, moderately, or severely
to a regional reduction in hyperemic MBF. This
is because reduced coronary vasodilator capacity in
patients with CAD is not merely a consequence of
ﬂow-limiting effects of any epicardial stenosis but
also is related to cardiovascular risk factor–induced
microvascular dysfunction (1).
The evaluation and interpretation of hyperemic
MBF and MFR with PET therefore needs to be set in
the clinical context with coronary anatomy and/or
microvascular dysfunction in patients with cardio-
vascular risk and/or CAD (1). It has been suggested
that for an epicardial stenosis $70%, reductions in
MFR <1.7 can be assumed to account, at least in
part, for increases in focal epicardial resistance us-
ing PET with 13N-ammonia or 82rubidium as a
myocardial ﬂow tracer (4). Additional help may also
come from PET-measured longitudinal hyperemic
MBF decreases from the base to the apex of the
heart (5). This diagnostic approach may provide
more speciﬁc information on epicardial resistance
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1477than conventional MFR (5,6) but requires further
investigation.
CONCORDANCE AND DISCORDANCE BETWEEN MFR
AND FFR. The strength of the investigation by Danad
et al. (2) lies in the use of invasively measured FFR as
reference for the [15O]H2O PET-determined cutoff
values of hyperemic MBF and MFR in the identiﬁca-
tion of hemodynamically (not just morphologically)
signiﬁcant CAD. Larger discordance between inva-
sively measured FFR and PET-derived MFR has been
reported (7). Such discordance can be attributed to
diffuse CAD and/or microvascular dysfunction that
lowers MFR without reduced FFR or a localized
pressure gradient commonly seen in patients with
CAD who have cardiovascular risk factors, such
as diabetes mellitus and arterial hypertension.
Conversely, vascular territories with coronary steno-
sis and reduced FFR (representing a localized pres-
sure gradient across the lesion) may have preserved
MFR on PET. This would reﬂect adequate hyperemic
compensatory ﬂow increases in resistance vessels
and/or the development of collaterals to the distal
perfusion bed (4). The presence of moderate to severe
stages of microvascular dysfunction may in fact
prevent submaximal or maximal hyperemic ﬂow
increases during pharmacological vasodilation of the
coronary arteriolar vessels, such that FFR measure-
ments may not fully reﬂect the potential functional,
downstream effect of focal coronary lesions on hy-
peremic ﬂow and may even be within “normal” range.
This may also be partly reﬂected by a gray zone of
FFR measurements ranging between 0.75 and 0.85
(8). Within this range, FFR measurement certainty
may decrease to <80%. Thus, FFR and MFR provide
distinctly different information regarding coronary
pathophysiology, but these ﬂow parameters comple-
ment each other in speciﬁc clinical scenarios (4).
THE POTENTIAL FOR “STRESS-ONLY” HYPEREMIC PET
MYOCARDIAL BLOOD FLOW STUDIES. Measuring rest
MBF in conjunction with vasodilator stress MBF and
computing MFR (which equals the ratio of MBF dur-
ing hyperemia to MBF at rest) offers a potential
advantage; if a percentage error is made (e.g., in the
arterial input function at rest) and the same error is
made during hyperemia, the errors will cancel out (9).
Therefore, when computing MFR, any systematic
underestimate or overestimate of errors may not
necessarily matter, provided the same percentage
error is made both at rest and during hyperemia (10).
The observations by Danad et al., however, also
signify an impact of age and sex on the diag-
nostic accuracy of quantitative [15O]H2O MBF mea-
surements. Resting MBF is commonly higher withincreasing age (linked to an age-related increase of
baseline myocardial work), which may lead to lower
MFR values (11,12). Although sex did not appear to
affect hyperemic MBF, resting MBF was higher in
female subjects even after correction for myocardial
workload. This difference may be related, at least in
part, to effects of estrogens on vascular tone in
women with CAD and/or sex-dependent lipid proﬁle
alterations (1). Given that hyperemic MBF was more
accurate than MFR for the overall detection of ﬂow-
limiting coronary artery stenoses and less affected
by the higher resting MBF in female and older sub-
jects, stress-only PET determination of hyperemic
MBF may be an alternative to MFR.
Higher predictive accuracy of hyperemic MBF over
MFR for identifying hemodynamically signiﬁcant CAD
has also been shown with 13N-ammonia PET (13).
Notably, in patients older than 70 years of age, hy-
peremic MBF appears to be lower (11,12). Apart from
evidence of deﬁcient neuroendocrine regulation of
the cardiovascular system with advancing age, a
diminished effect of exogenous applied adenosine on
vascular smooth muscle cell relaxation of the coronary
arteriolar vessels may account for these reductions in
hyperemic MBF in elderly patients (11). As for sex, the
authors observed that sensitivity and the positive
predictive value were lower in women than in men,
which again was balanced by a higher speciﬁcity and
negative predictive value in the detection of CAD.
Because sex does not appear to affect hyperemic MBF,
the observed higher diagnostic accuracy of [15O]H2O
PET in the detection of ﬂow-limiting CAD in women
than inmenmost likely is related to a lower prevalence
of CAD in women, as the authors state. Conse-
quently, given recent publications and public policies
on reducing radiation exposure and controlling ever-
growing diagnostic costs, single, stress-only PET
determination of hyperemic MBF with [15O]H2O (2) or
13N-ammonia (13) may be a potential solution.
CONCLUSIONS. PET-derived hyperemic MBF and
MFR show promise for noninvasively detecting ﬂow-
limiting, functionally relevant coronary artery ste-
nosis (2). Despite proven prognostic importance in
published reports, such absolute MBF values have
rarely been used clinically, but that may change with
the advent of several Food and Drug Administration–
approved quantitative software packages. The higher
diagnostic accuracy of stress-only hyperemic MBF
over MFR, when compared with FFR and invasive
coronary angiography, may be a welcome option in an
era demanding reduced costs and radiation exposure.
The latter may serve as the noninvasive “gatekeeper”
to limit unnecessary cardiac catheterization while
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1478accurately determining which patients would beneﬁt
from diagnostic coronary angiography and subse-
quent revascularization. Similar to the prospectively
conducted multicenter studies with FFR, whether
PET-guided hyperemic MBF and MFR parameters will
also translate into improved clinical and patient
outcomes after revascularization is a laudable goal to
pursue.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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